126 related articles for article (PubMed ID: 2516692)
41. [Comparative study of various rapid methods of determining fibrinogen transformation products in the diagnosis of intravascular coagulation and fibrinolysis].
Lychev VG; Momot AP; Cherkashin GV
Ter Arkh; 1984; 56(6):106-9. PubMed ID: 6474366
[TBL] [Abstract][Full Text] [Related]
42. Efficacy evaluation of D-dimer and modified criteria in overt and nonovert disseminated intravascular coagulation diagnosis.
Li WJ; Sha M; Ma W; Zhang ZP; Wu YJ; Shi DM
Int J Lab Hematol; 2016 Apr; 38(2):151-9. PubMed ID: 26833979
[TBL] [Abstract][Full Text] [Related]
43. Diagnosis of disseminated intravascular coagulation. Role of D-dimer.
Carr JM; McKinney M; McDonagh J
Am J Clin Pathol; 1989 Mar; 91(3):280-7. PubMed ID: 2646905
[TBL] [Abstract][Full Text] [Related]
44. Specific identification of fibrin polymers, fibrinogen degradation products, and crosslinked fibrin degradation products in plasma and serum with a new sensitive technique.
Connaghan DG; Francis CW; Lane DA; Marder VJ
Blood; 1985 Mar; 65(3):589-97. PubMed ID: 3971042
[TBL] [Abstract][Full Text] [Related]
45. The activation of neutrophil elastase-mediated fibrinolysis is not sufficient to overcome the fibrinolytic shutdown of disseminated intravascular coagulation associated with systemic inflammation.
Gando S; Hayakawa M; Sawamura A; Hoshino H; Oshiro A; Kubota N; Jesmin S
Thromb Res; 2007; 121(1):67-73. PubMed ID: 17397908
[TBL] [Abstract][Full Text] [Related]
46. [Fibrin and fibrinogen degradation products (FDP) in renal diseases. II. Serum and urinary FDP in different morphological forms of glomerulonephritis].
Ratajczak T; Rabczyński J; Szewczyk Z
Pol Arch Med Wewn; 1978 Apr; 59(4):429-40. PubMed ID: 662758
[No Abstract] [Full Text] [Related]
47. Urinary fibrin degradation products in childhood acute nephritis.
Dawson KP
N Z Med J; 1977 Oct; 86(597):332-4. PubMed ID: 272538
[TBL] [Abstract][Full Text] [Related]
48. Serum crosslinked fibrin (XDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrinolytic systems.
Hunt FA; Rylatt DB; Hart RA; Bundesen PG
Br J Haematol; 1985 Aug; 60(4):715-22. PubMed ID: 3896298
[TBL] [Abstract][Full Text] [Related]
49. Diagnostic efficacy of the D-dimer assay in disseminated intravascular coagulation (DIC).
Bick RL; Baker WF
Thromb Res; 1992 Mar; 65(6):785-90. PubMed ID: 1636167
[TBL] [Abstract][Full Text] [Related]
50. [Molecular markers of hemostatic mechanisms--FDP-D Dimer].
Hada M
Rinsho Byori; 1989 Mar; 37(3):240-7. PubMed ID: 2664280
[No Abstract] [Full Text] [Related]
51. Problems of diagnosis of disseminated intravascular coagulation (DIC).
Bowie EJ; Owen CA
Southeast Asian J Trop Med Public Health; 1979 Sep; 10(3):325-7. PubMed ID: 515796
[TBL] [Abstract][Full Text] [Related]
52. Monoclonal antibodies to crosslinked fibrin degradation products (XL-FDP). I. Characterization and preliminary evaluation in plasma.
Gaffney PJ; Creighton LJ; Perry MJ; Callus M; Thorpe R; Spitz M
Br J Haematol; 1988 Jan; 68(1):83-90. PubMed ID: 3345297
[TBL] [Abstract][Full Text] [Related]
53. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
[TBL] [Abstract][Full Text] [Related]
54. Fibrinogen/fibrin degradation products and D-dimer in clinical practice: interpretation of discrepant results.
Sato N; Takahashi H; Shibata A
Am J Hematol; 1995 Mar; 48(3):168-74. PubMed ID: 7864025
[TBL] [Abstract][Full Text] [Related]
55. Analysis of elevated fibrin(ogen) degradation product levels in patients with liver disease.
vanDeWater L; Carr JM; Aronson D; McDonagh J
Blood; 1986 May; 67(5):1468-73. PubMed ID: 2938648
[TBL] [Abstract][Full Text] [Related]
56. Prototype quantitative assay for fibrinogen/fibrin degradation products. Clinical evaluation.
Sigal SH; Cembrowski GS; Shattil SJ; Brown NM; Schifreen RS; Schwartz MW
Arch Intern Med; 1987 Oct; 147(10):1790-3. PubMed ID: 3662708
[TBL] [Abstract][Full Text] [Related]
57. [A novel molecular marker for thrombus formation and life prognosis--clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)].
Koga S
Rinsho Byori; 2004 Apr; 52(4):355-61. PubMed ID: 15164605
[TBL] [Abstract][Full Text] [Related]
58. Urinary fibrinogen and fibrin fragments in children with renal disease.
Yoshioka K; Iseki T; Akano N; Uraoka Y; Miyata H; Maki S
Nephron; 1982; 32(2):135-9. PubMed ID: 7177290
[TBL] [Abstract][Full Text] [Related]
59. The determination of fibrinolytic degradation products in concentrated urine after renal transplantation.
Ekberg M; Bergentz SE; Hedner U; Nilsson IM
Scand J Urol Nephrol; 1976; 10(1):56-62. PubMed ID: 775625
[TBL] [Abstract][Full Text] [Related]
60. Fibrin degradation products, fibrin monomer and soluble fibrin in disseminated intravascular coagulation.
Horan JT; Francis CW
Semin Thromb Hemost; 2001 Dec; 27(6):657-66. PubMed ID: 11740689
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
